AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02773537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adductor canal catheter and selective tibial block
Description: This nerve block is believed to cause numbness only, without any muscle weakness. A catheter remains in place for up to 36 hours after surgery for the purpose of adding additional medication should the patient require it to control pain. This technique causes both the front and the back of the knee to be numb.
Study NCT02773537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adductor canal catheter only
Description: This nerve block is believed to cause numbness only, without any muscle weakness. A catheter remains in place for up to 36 hours after surgery for the purpose of adding additional medication should the patient require it. This technique causes only the front of the knee to be numb
Study NCT01840163 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Static version of CanSORT tool
Study NCT01840163 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CanSORT Online Tool
Study NCT03607669 — intervention group
Intervention type: OTHER
Intervention: Mangafodipir trisodium
Description: Manganese-based MRI contrast agent
Study NCT03678363 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Tai chi chuan
Description: Tai chi sessions will consist of repetition of simple and basic movements focusing mainly on breating, relaxation and body diagram. This Chinese martial art also includes coordination exercises of body parts (legs, arms, pelvis and spine), looseness and limbering up of joints and muscles.
Study NCT03678363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai chi chuan
Description: Tai chi sessions will consist of repetition of simple and basic movements focusing mainly on breating, relaxation and body diagram. This Chinese martial art also includes coordination exercises of body parts (legs, arms, pelvis and spine), looseness and limbering up of joints and muscles.
Study NCT01093560 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fat feeding
Description: Each feeding will consist of 473 mL of nonfat milk and 50 gms oil. The oil will be high in saturated fat, monounsaturated fat or polyunsaturated fat.
Study NCT00680498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Ranibizumab 0.5 mg
Study NCT05531344 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Composite Steep-pulse Treatment Device
Description: Applying the Composite Steep-pulse Treatment Device to treat the patients with Benign Prostatic Hyperplasia
Study NCT05531344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin Hydrochloride Capsules
Description: Applying Tamsulosin Hydrochloride Capsules to treat the patients with Benign Prostatic Hyperplasia
Study NCT02018510 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1 mg/kg, single dose IV administration of 3BNC117
Description: 1 mg/kg, single dose IV administration of 3BNC117
Study NCT02018510 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3 mg/kg, single dose IV administration of 3BNC117
Description: 3 mg/kg, single dose IV administration of 3BNC117
Study NCT01633112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fingolimod
Description: capsule
Study NCT00680498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab plus Photodynamic therapy
Description: Ranibizumab 0.5mg, combined with photodynamic therapy with Verteporfin (dosage per label)
Study NCT03293511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal oxytocin
Description: 24 IU of oxytocin nasal spray will be applied to each subject.
Study NCT01632423 — intervention group
Intervention type: DRUG
Intervention: bimatoprost 0.01%
Description: Patients with POAG or OHT prescribed Lumigan® (bimatoprost 0.01%) treatment in a dose determined by the physician prior to study entry
Study NCT04404907 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: This is a secondary analysis of registry data.
Study NCT03293511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal placebo
Description: 24 IU of of placebo nasal spray will be applied to each subject.
Study NCT01633112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glatiramer acetate
Description: subcutaneous injection
Study NCT02018510 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10 mg/kg, single dose IV administration of 3BNC117
Description: 10 mg/kg, single dose IV administration of 3BNC117
Study NCT04211571 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theranova 400 dialyzer
Description: Hemodialysis using Theranova 400 dialyzer
Study NCT04211571 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-flux dialyzer
Description: Hemodialysis using high-flux dialyzer
Study NCT04541251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab + Nab-paclitaxel + Carboplatin
Description: The patients will receive three cycles (one cycle is defined as every 21 days +/- 3 days) of neoadjuvant therapy with camrelizumab 200 mg, nab-paclitaxel 260 mg/m2, and carboplatin AUC 5. This will then be followed by surgery.
Study NCT01561027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNV1014802
Description: Administered as specified in treatment arm.
Study NCT01561027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in treatment arm
Study NCT02018510 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30 mg/kg, single dose IV administration of 3BNC117
Description: 30 mg/kg, single dose IV administration of 3BNC117
Study NCT00112398 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extended interventions by advanced level prehospital providers
Description: may include rapid sequence intubation (RSI) airway management, blood transfusions, surgical procedures, etc.
Study NCT00112398 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extended interventions by advanced level prehospital providers
Description: may include rapid sequence intubation (RSI) airway management, blood transfusions, surgical procedures, etc.
Study NCT02318576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Computerized Cognitive Training: The online computer training program will be administered on the participants' home computer. The training program will consist of a total of 36 sessions (3 times/week for 12 weeks). Each session will last no more than 60 minutes and consist of five different cognitive exercises designed to improve cognitive processing speed, memory and executive function. All exercises will involve visual stimuli and a motor response (key or button press). Exercises will be adaptive to participants' individual ability and start with minimal difficulty.
Study NCT01656174 — intervention group
Intervention type: DEVICE
Intervention: Procleix Dengue Virus Assay
Description: in vitro diagnostic assay
Study NCT00786851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide and Dexametasone
Description: Lenalidomide will be supplied as 5 mg and 25 mg capsules for oral administration.Dexamethasone (Soldesam 0.2%) will be supplied as 20 mg liquid for oral administration (1 bottle = 20 mg; daily dose = 2 bottles = 40 mg).
Study NCT01475071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metvix and natural daylight PDT
Description: Methyl aminolevulinate, cream 160mg/g.One session at baseline and a second session administration at week 12 for lesions showing non-complete response and new lesions on target area.
Study NCT01475071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metvix and conventional PDT
Description: Methyl aminolevulinate, cream, 160mg/g. One session at baseline and a second session administration at week 12 for lesions showing non-complete response and new lesions on target area.
Study NCT00736177 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Embryo cryopreservation
Description: Subjects in the Test group will have their embryos cryopreserved for transfer in a subsequent cycle.
Study NCT00736177 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fresh embryo transfer
Description: Subjects in the Control group will receive fresh embryo transfer.
Study NCT01116505 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gluten-free diet
Description: gluten-containing cereals removed from diet
Study NCT03776344 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality intervention - Oculus Rift HD
Description: During the VR experience patients will have the opportunity to choose from different VR environments (VR application - Nature Treks VR) and explore them using Oculus Rift Device.
Study NCT01398085 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: I131 1.1 GBq
Description: Radio-iodine
Study NCT03257228 — intervention group
Intervention type: GENETIC
Intervention: comparative semiquantitative immunohistochemistry
Study NCT02374216 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Insertion of dental implants
Description: Evaluation of the failure rate of all dental implants, of any brand, inserted between September 1st 2014 to August 31st 2017
Study NCT00550251 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupressure Wrist Bands (Sea-Bands)
Description: Elasticated wrist bands with active bead pressing on Pericardium 6 acupressure points bilaterally.
Study NCT00550251 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo wristbands
Description: Elasticated wrist bands without active bead.
Study NCT04487184 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Kinesiology taping
Description: Recently, kinesiology tape is a common intervention in clinic and sport. The tension caused by tape elasticity and attachment techniques affects the effects that kinesiology tape produces, such as pain relief, circulation increase, proprioception enhancement, and muscle contraction improvement.
Study NCT04487184 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Kinesiology taping
Description: Recently, kinesiology tape is a common intervention in clinic and sport. The tension caused by tape elasticity and attachment techniques affects the effects that kinesiology tape produces, such as pain relief, circulation increase, proprioception enhancement, and muscle contraction improvement.
Study NCT04487184 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesiology taping
Description: Recently, kinesiology tape is a common intervention in clinic and sport. The tension caused by tape elasticity and attachment techniques affects the effects that kinesiology tape produces, such as pain relief, circulation increase, proprioception enhancement, and muscle contraction improvement.
Study NCT01107730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: VitC intravenously (2g/day \[500mgX4\] for 2 days prior to surgery, and postoperatively for 4 days
Study NCT01107730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Carnitine
Description: L-Carnitine intravenously (2 gr/day \[1grX2\] for 2 days prior to surgery, and postoperatively for 4 days
Study NCT01107730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01375894 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: imitation assessment using the 5-dt data glove.
Description: measuring the speed of the hand during imitation
Study NCT01375894 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: imitation assessment using the 5-dt data glove.
Description: measuring the speed of the hand during imitation
Study NCT03037229 — intervention group
Intervention type: DEVICE
Intervention: Smartphone ECG
Study NCT03037229 — intervention group
Intervention type: DEVICE
Intervention: Standard 12-lead ECG
Study NCT04487184 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiology taping
Description: Recently, kinesiology tape is a common intervention in clinic and sport. The tension caused by tape elasticity and attachment techniques affects the effects that kinesiology tape produces, such as pain relief, circulation increase, proprioception enhancement, and muscle contraction improvement.
Study NCT00972946 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Administration of autologous Endorem-labelled mononuclear cells intravenously
Description: single dose
Study NCT00972946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of Endorem
Description: single dose, intravenous
Study NCT02315612 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD22-CAR
Description: CD22-CAR cells will be infused on Day 0 after induction chemotherapy regimen.
Study NCT03600441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abexinostat
Description: Abexinostat tosylate salt is formulated into an oral tablet formulation and is available in 20 mg strength.
Study NCT02018510 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10 mg/kg, two doses IV of 3BNC117
Description: 10 mg/kg, two IV administrations of 3BNC117 at weeks 0 and 12
Study NCT02018510 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30 mg/kg, two doses IV of 3BNC117
Description: 30 mg/kg, two IV administrations of 3BNC117 at weeks 0 and 12
Study NCT01224353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lipoic acid
Description: Tablet, 600mg, for oral use, 30 min before breakfast, once daily for 6 weeks
Study NCT01224353 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, placebo, 1-week single-blind placebo treatment then, 30 min before breakfast, once daily for 6 weeks
Study NCT01125527 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Monovalent glyco-conjugated vaccine against Haemophilus influenzae type b (Hib)
Description: a single dose was administered
Study NCT01125527 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus toxoid polysaccharide-conjugated vaccine against Haemophilus influenzae type b (Hib)
Description: a single dose was administered
Study NCT00944190 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management intervention
Description: Brief counseling technique, self-management,
Study NCT00944190 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Educational information about pain, fatigue, depression, and cognitive difficulties in multiple sclerosis.
Study NCT01715922 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fluconazole
Description: Induction treatment for 2 weeks: Fluconazole (1600mg/j) Consolidation treatment for 8 weeks: fluconazole (800 mg/j)
Study NCT01715922 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Flucytosine
Description: Flucytosine (100 mg/kg/j) for 2 weeks
Study NCT01715922 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: lumbar punctures
Description: lumbar punctures to control intracranial pressure
Study NCT02225015 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up Telephone Genetic Counselling
Description: Individualized theoretical genetic counselling among women with BRCA mutations to assess the impact it has on the uptake of cancer prevention strategies.
Study NCT04323527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine diphosphate
Description: 150mg chloroquine diphosphate tablets. Note: Tablets used in the study were Chloroquine Diphosphate (produced by Farmanguinhos/Fiocruz), and the dosing stated in the clinicaltrials.gov refers to chloroquine base (in mg).
Study NCT04323527 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chloroquine diphosphate
Description: 150mg chloroquine diphosphate tablets. Note: Tablets used in the study were Chloroquine Diphosphate (produced by Farmanguinhos/Fiocruz), and the dosing stated in the clinicaltrials.gov refers to chloroquine base (in mg).
Study NCT02017873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peroxide Carbamide 10% - Dental bleaching treatment
Description: During 3 hours in 3 weeks of bleaching in both groups in healthy patients and smokers patients
Study NCT02017873 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peroxide Carbamide 10% - Dental bleaching treatment
Description: During 3 hours in 3 weeks of bleaching in both groups in healthy patients and smokers patients
Study NCT01710722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caffeine and ephedrine
Description: Caffeine 200 mg tablets and ephedrine HCl 25 mg tablets three times a day with placebo leptin A-200 subcutaneously once daily.
Study NCT01710722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leptin A
Description: Leptin A-200 20 mg subcutaneously once daily and placebo tablets of caffeine and ephedrine three times a day.
Study NCT01710722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caffeine, ephedrine, and leptin A
Description: Caffeine 200 mg tablets and ephedrine HCl tablets 25 mg three times a day with leptin A-200 20 mg subcutaneously once daily.
Study NCT04418219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: alkylating agent used in the treatment of several forms of cancer including leukemias, lymphomas and breast cancer.
Study NCT04418219 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM
Description: Breast Cancer Vaccine SV-BR-1-GM, Bria-IMT, GM-CSF Gene-transfected Breast Cancer Vaccine SV-BR-1-GM, SV-BR-1 Breast Cancer Cell Line Vaccine, SV-BR-1-GM, SV-BR-1-GM Vaccine
Study NCT04418219 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 1374853-91-4, Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218'')-disulfide with Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'''':229-229'''')-bisdisulfide, Keytruda, Lambrolizumab, MK-3475, PEMBROLIZUMAB, SCH 900475
Study NCT04418219 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alpha 2b-like Protein
Description: Novaferon, Recombinant IFN Alfa-2b-like Protein
Study NCT04418219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04418219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life Assessment
Description: Ancillary studies
Study NCT00529763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, Oral, 70 mg BID (AD CML) or 100 mg QD (Chronic CML), once or twice daily dependent on disease stage, until subjects meet discontinuation (DC) criteria for study
Study NCT03293563 — intervention group
Intervention type: PROCEDURE
Intervention: Radical nephrectomy versus partial nephrectomy (according surgeon judgement)
Study NCT01704560 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coversheet to Informed Consent
Description: The intervention is a one page cover sheet to be affixed to the front of the standard permission form for the trial for which permission is being sought (attached to application). The form will identify the study as research and contain sections that include investigator contact information, the purpose of the study, a brief description of the study procedures, the alternatives, the voluntary nature, the risks, the potential benefits, a discussion of privacy and confidentiality, the costs and the payments. Each topic will also contain a reference to the page in the consent containing the full description of the topic. The form is designed to have a reading level no higher than 6th to 8th grade. Parents will also receive the full permission form, and all required signatures will still be collected on the permission form.
Study NCT01192477 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Ozone
Description: All subjects will have a 3-hour exposure to clean air, a 3-hour exposure to clean air with lower ozone (0.1 ppm), and a 3-hour exposure to clean air with higher ozone (0.2 ppm). Exposures will take place at least 3 weeks apart. Order of exposure will be randomized for each subject.
Study NCT03083860 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: BEI
Description: BrainMARC Ltd. has demonstrated in recent years the ability to extract effective attention markers from averaged ERP waves sampled with a single EEG channel (two electrodes). In addition, BrainMARC has developed a template matching method to extract the attention-related markers at the single-trial level. An index (termed Brain Engagement Index - BEI) can then be generated from a 1-minute, single-channel sample.
Study NCT01192477 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ozone
Description: All subjects will have a 3-hour exposure to clean air, a 3-hour exposure to clean air with lower ozone (0.1 ppm), and a 3-hour exposure to clean air with higher ozone (0.2 ppm). Exposures will take place at least 3 weeks apart. Order of exposure will be randomized for each subject.
Study NCT02808091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIFOX-Bortezomib
Description: GIFOX-Bortezomib will be given every 21 days for 4 cycles
Study NCT02808091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIFOX-Bortezomib
Description: GIFOX-Bortezomib will be given every 21 days for a total of 6 cycles.
Study NCT02808091 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: a minimum of 50 Gy of IMRT to tumor bed and neck (5 weeks)